Septerna (SEPN) Competitors $5.80 -0.09 (-1.53%) Closing price 04:00 PM EasternExtended Trading$5.96 +0.17 (+2.84%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends SEPN vs. MESO, CNTA, BHC, HRMY, CGON, TARS, JANX, AGIO, NAMS, and IDYAShould you be buying Septerna stock or one of its competitors? The main competitors of Septerna include Mesoblast (MESO), Centessa Pharmaceuticals (CNTA), Bausch Health Companies (BHC), Harmony Biosciences (HRMY), CG Oncology (CGON), Tarsus Pharmaceuticals (TARS), Janux Therapeutics (JANX), Agios Pharmaceuticals (AGIO), NewAmsterdam Pharma (NAMS), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Septerna vs. Mesoblast Centessa Pharmaceuticals Bausch Health Companies Harmony Biosciences CG Oncology Tarsus Pharmaceuticals Janux Therapeutics Agios Pharmaceuticals NewAmsterdam Pharma IDEAYA Biosciences Septerna (NASDAQ:SEPN) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and risk. Is SEPN or MESO more profitable? Company Net Margins Return on Equity Return on Assets SepternaN/A N/A N/A Mesoblast N/A N/A N/A Do analysts rate SEPN or MESO? Septerna currently has a consensus price target of $34.00, suggesting a potential upside of 475.78%. Mesoblast has a consensus price target of $18.00, suggesting a potential upside of 9.39%. Given Septerna's higher probable upside, analysts plainly believe Septerna is more favorable than Mesoblast.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Mesoblast 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor SEPN or MESO? Mesoblast received 407 more outperform votes than Septerna when rated by MarketBeat users. However, 83.33% of users gave Septerna an outperform vote while only 70.31% of users gave Mesoblast an outperform vote. CompanyUnderperformOutperformSepternaOutperform Votes583.33% Underperform Votes116.67%MesoblastOutperform Votes41270.31% Underperform Votes17429.69% Does the media refer more to SEPN or MESO? In the previous week, Septerna had 13 more articles in the media than Mesoblast. MarketBeat recorded 16 mentions for Septerna and 3 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.68 beat Septerna's score of 0.04 indicating that Mesoblast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 0 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Mesoblast 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in SEPN or MESO? 1.4% of Mesoblast shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has higher earnings and valuation, SEPN or MESO? Septerna has higher earnings, but lower revenue than Mesoblast. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepterna$981K267.28N/AN/AN/AMesoblast$5.90M354.34-$87.96MN/AN/A SummaryMesoblast beats Septerna on 8 of the 12 factors compared between the two stocks. Get Septerna News Delivered to You Automatically Sign up to receive the latest news and ratings for SEPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEPN vs. The Competition Export to ExcelMetricSepternaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$262.20M$7.07B$5.80B$8.99BDividend YieldN/A2.87%4.78%3.85%P/E RatioN/A6.0226.3218.88Price / Sales267.28316.05452.0876.91Price / CashN/A67.8344.0437.47Price / BookN/A6.757.644.66Net IncomeN/A$138.11M$3.18B$245.69M7 Day Performance-54.44%-1.85%-1.66%-2.22%1 Month Performance-68.42%-1.39%0.41%-1.95%1 Year PerformanceN/A-2.92%17.47%14.12% Septerna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEPNSepternaN/A$5.80-1.5%$34.00+486.2%N/A$257.54M$981,000.000.00N/AAnalyst DowngradeAnalyst RevisionNews CoverageGap UpMESOMesoblast0.8266 of 5 stars$17.90-2.9%$18.00+0.6%+757.2%$2.27B$5.90M0.0080Upcoming EarningsCNTACentessa Pharmaceuticals3.461 of 5 stars$17.07-3.1%$25.83+51.3%+57.1%$2.25B$6.85M-11.16200Insider TradeHigh Trading VolumeBHCBausch Health Companies3.8517 of 5 stars$6.15-3.6%$7.42+20.6%-16.5%$2.22B$8.76B-12.8220,270Earnings ReportNews CoverageHRMYHarmony Biosciences4.724 of 5 stars$38.98-0.3%$55.00+41.1%+5.7%$2.22B$582.02M18.47200Analyst ForecastAnalyst RevisionNews CoverageCGONCG Oncology1.8516 of 5 stars$28.52+0.1%$63.88+124.0%-36.4%$2.17B$200,000.000.0061News CoverageTARSTarsus Pharmaceuticals1.4327 of 5 stars$50.22-3.8%$56.00+11.5%+60.2%$1.92B$17.45M-13.1850JANXJanux Therapeutics3.1281 of 5 stars$36.37-2.2%$89.90+147.2%+273.2%$1.91B$13.05M-31.0930AGIOAgios Pharmaceuticals4.3459 of 5 stars$33.22-0.2%$56.33+69.6%+24.5%$1.89B$26.82M2.92390Earnings ReportShort Interest ↓NAMSNewAmsterdam Pharma3.308 of 5 stars$19.91+2.6%$41.60+108.9%-10.0%$1.84B$14.09M0.004Upcoming EarningsIDYAIDEAYA Biosciences3.8433 of 5 stars$21.00+1.2%$53.58+155.2%-50.6%$1.82B$23.39M-9.0180Gap Up Related Companies and Tools Related Companies MESO Competitors CNTA Competitors BHC Competitors HRMY Competitors CGON Competitors TARS Competitors JANX Competitors AGIO Competitors NAMS Competitors IDYA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SEPN) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Septerna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Septerna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SEPN Stock Alerts